18364185. ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOF simplified abstract (Genentech, Inc.)

ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOF

Organization Name

Genentech, Inc.

Inventor(s)

Gerald R. Nakamura of San Francisco CA (US)

Dhaya Seshasayee of Cupertino CA (US)

Menno Van Lookeren Campagne of San Francisco CA (US)

Tiffany Wong of South San Francisco CA (US)

Jia Wu of Foster City CA (US)

Hongkang Xi of South San Francisco CA (US)

Jack Bevers, Iii of San Francisco CA (US)

Hiu Nam Chan of South San Francisco CA (US)

Laetitia Comps-agrar of Foster City CA (US)

Racquel Corpuz of South San Francisco CA (US)

ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOF - A simplified explanation of the abstract

This abstract first appeared for US patent application 18364185 titled 'ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOF

Simplified Explanation

The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).

• IL-33 antibodies are developed for the treatment of IL-33 mediated disorders, particularly ocular disorders like AMD.
• The invention includes methods for producing IL-33 antibodies and utilizing them for therapeutic purposes.

Potential Applications

IL-33 antibodies can be used in the treatment of various IL-33 mediated disorders, including ocular diseases like AMD.

Problems Solved

This technology addresses the need for effective treatments for IL-33 mediated disorders, which can have significant impacts on patients' health and quality of life.

Benefits

The IL-33 antibodies offer a promising therapeutic option for patients suffering from IL-33 mediated disorders, potentially improving their outcomes and quality of life.

Potential Commercial Applications

The IL-33 antibodies could have commercial applications in the pharmaceutical industry, specifically in the development of treatments for ocular disorders and other IL-33 mediated conditions.

Possible Prior Art

Prior research may exist on IL-33 antibodies and their potential applications in treating IL-33 mediated disorders. Further investigation into existing patents and publications in this area could provide more insight into the prior art related to this technology.

How does this technology compare to existing treatments for IL-33 mediated disorders?

The article does not provide a direct comparison between IL-33 antibodies and other treatments currently available for IL-33 mediated disorders. Further research or clinical trials may be needed to evaluate the efficacy and safety of IL-33 antibodies in comparison to existing therapies.

What are the potential challenges in developing and commercializing IL-33 antibodies for the treatment of ocular disorders?

The article does not address the potential obstacles or regulatory hurdles that may arise in the development and commercialization of IL-33 antibodies for ocular disorders. Understanding these challenges could be crucial for successful implementation of this technology in clinical practice.

Original Abstract Submitted

The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).